Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …

There is a large unmet medical need to develop disease-modifying treatment options for
individuals with age-related degenerative diseases of the central nervous system. The …

The sigma 2 receptor (σ2R) was described pharmacologically more than three decades ago,
but its molecular identity remained obscure until recently when it was identified as …

Introduction Amyloid beta (Aβ) oligomers are one of the most toxic structural forms of the Aβ
protein and are hypothesized to cause synaptotoxicity and memory failure as they build up …

Drug development efforts that focused on single targets failed to provide effective treatment
for Alzheimer's disease (AD). Therefore, we designed cholinesterase inhibition (ChEI) …

CT1812 is a novel, brain penetrant small molecule modulator of the sigma-2 receptor (S2R)
that is currently in clinical development for the treatment of Alzheimer's disease (AD) …

Sigma (σ) receptors are a class of unique proteins with two subtypes: the sigma-1 (σ1)
receptor which is situated at the mitochondria-associated endoplasmic reticulum (ER) …

Membrane contact sites (MCSs) between endosomes and the endoplasmic reticulum (ER)
are thought to act as specialized trigger zones for Ca 2+ signaling, where local Ca 2+ …

Abstract α‐Synuclein oligomers are thought to have a pivotal role in sporadic and familial
Parkinson's disease (PD) and related α‐synucleinopathies, causing dysregulation of protein …

Conspectus Scientific excursions into the unknown are often characterized by unanticipated
twists and turns that may lead in directions that never could have been predicted. Decisions …